Pharmaceutical Era

Search your requirement

  • Home
  • Press Releases
    • Submit Release
  • Events
  • Reach Us

Social media

Pharmaceutical Era Pharmaceutical Era
  • Home
  • Press Releases
    • Submit Release
  • Events
  • Reach Us
MilliporeSigma receives the industry
MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing
Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics
Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics
Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season
Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season
OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award
OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award
Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis
Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis
ProJenX announces the formation of its Clinical Advisory Board
ProJenX announces the formation of its Clinical Advisory Board
Citius Pharmaceuticals
Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma
NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients
NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients
Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits
Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.
Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic
Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic
FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma
FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma

Featured Press Releases

With Fifth NovaSeq X Plus System in Europe, Novogene Europe Expands Sequencing Capabilities

With Fifth NovaSeq X Plus System in Europe, Novogene Europe Expands Sequencing Capabilities

  • By Novogene
  • Novogene
  • 07 Jul 2025
Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model: Tinnitus Research

Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model: Tinnitus Research

  • By AudioCure
  • AudioCure
  • 07 Jul 2025
The European Commission grants Aurobindo Pharma approval to market the cancer drug, Dazublys

The European Commission grants Aurobindo Pharma approval to market the cancer drug, Dazublys

  • By Aurobindo Pharma
  • Aurobindo Pharma
  • 02 Jul 2025
Fresenius Expands Biosimilars Portfolio with Denosumab Launch in the U.S

Fresenius Expands Biosimilars Portfolio with Denosumab Launch in the U.S

  • By Fresenius Kabi
  • Fresenius Kabi
  • 01 Jul 2025
Seraphina Therapeutics Announces C15:0 Reverses Key Aspects of Cellular Fragility Syndrome in a Second Model

Seraphina Therapeutics Announces C15:0 Reverses Key Aspects of Cellular Fragility Syndrome in a Second Model

  • By Seraphina Therapeutics
  • Seraphina Therapeutics
  • 01 Jul 2025
Neurocrine Biosciences Presents New Post-Hoc Data from the KINECT®-HD Study, Demonstrating a Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington

Neurocrine Biosciences Presents New Post-Hoc Data from the KINECT®-HD Study, Demonstrating a Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea

  • By Neurocrine Biosciences, Inc.
  • Neurocrine Biosciences, Inc.
  • 30 Jun 2025
Log in
Show
  • Create an account
  • Forgot your username?
  • Forgot your password?
Webinar: Leverage AI for Operational Excellence and Strategic Cost Management

Most Popular

  • Abzena Launches LabZient™, an Analytical Platform to Expedite the Path to IND for Antibodies
    Abzena Launches LabZient™, an Analytical Platform to Expedite the Path to IND for Antibodies
    By Abzena
    Feb 08
  • Hoth Therapeutics teams up with OnTargetx R&D to further research for the cancer-fighting HT-KIT therapeutic
    Hoth Therapeutics teams up with OnTargetx R&D to further research for the cancer-fighting HT-KIT therapeutic
    By Hoth Therapeutics, Inc.
    Feb 10
  • At DDW’25, NImmune Biopharma will present the first-ever head-to-head clinical and translational results for Omilancor versus the leading anti-TL1A in IBD, demonstrating superiority and complementarity
    At DDW’25, NImmune Biopharma will present the first-ever head-to-head clinical and translational results for Omilancor versus the leading anti-TL1A in IBD, demonstrating superiority and complementarity
    By NImmune Biopharma
    May 06
August   2025
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

  • Login page
  • Registration
  • Edit Profile
  • Forgot Password

Discover

  • About Us
  • Terms Of Use
  • Privacy Policy
  • FAQs

Engage with Us

  • Search on Site
  • Post Press Release
  • Promote Brand
  • List Your Event

Subscribe for e-Newsletter Monthly

Subscribe to the Pharmaceutical Era newsletter to receive timely updates from your favorite products.
loader
Antispam refresh
© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. To find out more, please click here.